3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Breast
1
Conditions
Glioblastoma
4
Pancreatic Neoplasms
3
Multiple Myeloma
3
Neoplasms
2
Glioma
2
Thrombocythemia, Essential
1
Recurrence
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Polycystic Ovary Syndrome
1
Oligodendroglioma
1
Obesity
1
Neoplasms, Plasma Cell
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Gliosarcoma
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Astrocytoma
1
Interventions
Cyclophosphamide
41
fludarabine
31
Dexamethasone
27
venetoclax
25
Cytarabine
22
Rituximab
16
pembrolizumab
15
fludarabine phosphate
14
Filgrastim
12
Etoposide
12
Lenalidomide
11
Vincristine
10
Gemcitabine
10
Azacitidine
10
pomalidomide
9
Interleukin-2
9
Granulocyte Colony-Stimulating Factor
9
Doxorubicin
9
Calcium Dobesilate
9
carfilzomib
8
Topotecan
8
Nivolumab
8
Methotrexate
8
Everolimus
8
Decitabine
8
Bortezomib
8
Melphalan
7
Cisplatin
7
Vorinostat
6
Injections
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Recurrence
×
Ascorbic Acid
×
Clear all
NCT04150042
2026-01-29
SHARON
General Oncology, Inc.
Phase 1
Recruiting
24 enrolled